Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06121180 · ClinicalTrials.gov registry record · Phase 2

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

A Phase 2 study of Metastatic Uveal Melanoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Recruiting
Registry status
Phase 2
Development phase
32
Enrollment target
4
Study locations

NCT06121180: Recruiting Phase 2 study of Metastatic Uveal Melanoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

NCT06121180 is a Phase 2 study of Metastatic Uveal Melanoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 32 participants, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (75% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06121180, a Phase 2 study of Metastatic Uveal Melanoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

RECRUITING
Registry status
Phase 2
Development phase
32 participants
Enrollment target
4
Study locations

Study Summary

The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can make tumors shrink or stop growing.

Primary Outcome

objective response rate as defined by Complete response (CR) plus partial response (PR) as assessed by RECIST criteria version 1.1.

Conditions Studied

Metastatic Uveal Melanoma

Interventions

  • DRUG Cemiplimab
  • DRUG ZIV-Aflibercept

Study Locations (4)

California

  • The Angeles Clinic and Research Institute - Los Angeles

Florida

  • Moffitt Cancer Center - Tampa

Illinois

  • University of Chicago Medical Center - Chicago

New York

  • Northwell Health Center for Advanced Medicine - New Hyde Park

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2024-11-04
Est. Completion 2030-10-31
Phase Phase 2
H. Lee Moffitt Cancer Center and Research Institute

502 total trials

What NCT06121180 shows while recruiting

NCT06121180 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (75% lower).

The record links to 1 condition, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.

NCT06121180 reports a single indexed study location in California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06121180 about?

NCT06121180 is a clinical study titled "Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma". The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Zi...

What is the current status of trial NCT06121180?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2024-11-04. Estimated completion is 2030-10-31.

What conditions does trial NCT06121180 study?

This clinical trial studies the following conditions: Metastatic Uveal Melanoma.

What interventions are being tested in trial NCT06121180?

The interventions under investigation include: Cemiplimab (DRUG), ZIV-Aflibercept (DRUG).

Who is sponsoring clinical trial NCT06121180?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06121180 being conducted?

This trial has 4 study locations across California, Florida, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Uveal Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06121180's enrollment target sits among peer trials

32 10th of 14 higher than 5 of 14 other Metastatic Uveal Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06121180

Source: ClinicalTrials.gov NCT06121180, the US trial registry maintained by the National Library of Medicine. NCT06121180 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.